MarzAA

February 15, 2019February 15, 2019

Preliminary Data Further Show MarzAA’s Potential to Prevent Bleedings

News

Clinical data from the ongoing Phase 2/3 trial data evaluating MarzAA (marzeptacog alfa activated) in patients with Hemophilia A or B with inhibitors continues to demonstrate the treatment’s potential ... Read more

January 2, 2019January 11, 2019

Catalyst Announces Updates on Two Lead Compounds for Hemophilia

News

Catalyst Biosciences recently announced updates on two of its lead compounds — Factor VIIa (FVIIa) marzeptacog alfa (activated) (MarzAA) and Factor IX (FIX) dalcinonacog alfa (DalcA) — for treatment of hemophilia A or B with inhibitors, and ... Read more

August 20, 2018August 20, 2018

Phase 2/3 Clinical Trial of MarzAA Shows Promise in Hemophilia Treatment

News

Catalyst Biosciences announced positive interim results from a Phase 2/3 clinical trial (NCT03407651) of the Factor VIIa variant marzeptacog alfa (activated) (MarzAA) in the preventative treatment of patients with ... Read more

January 8, 2018

Catalyst Biosciences Starts Phase 2/3 Trial of Therapy to Prevent Hemophilia Bleeding Episodes

News

Catalyst Biosciences has begun enrolling patients in a Phase 2/3 clinical trial of marzeptacog alfa (activated) as a preventive treatment for hemophilia A or B. Some patients develop immune responses — ... Read more

Pin It on Pinterest